Monday, October 25, 2021

    Latest Posts

    Virtual Event: The evolving landscape for biosimilars – Boston, Massachusetts

    Boston, Massachusetts 2021-09-30 09:55:09 –

    Editor’s Note: The live stream of the event will be embedded below 1:00 pm Eastern Standard Time.

    NSiosimilars were expected to be a solution to the soaring cost of prescription drugs to treat many illnesses. Have they reached their potential?

    Some people see promising signs of increased adoption of these therapies, which are made from living cells and are nearly identical to their biological counterparts. Others are afraid that they are meeting resistance.


    STAT’s Ed Silverman convenes a discussion of what is needed to create a functioning biosimilar market in the United States.

    Featured Speakers:


    • Madeleine A. Feldmann, MD, FACR, President, Union of State Rheumatoid Organizations; Clinical Associate Professor, School of Medicine, Tlane University
    • Sonia T. Oscoway, PharmD, BCMAS, DPLA, Vice President, Biosimilar, Cardinal Health
    • Gillian Woollet, MA, DPhil, Senior Researcher, Avalere Health
    • Ed Silverman, Pharmalot columnist, STAT (Moderator)
    • Sanjin Pack, Samsung Bioepis, Executive Vice President and Commercial Leader (Sponsor speaker)

    jQuery( window ).on( ‘load’, function() {
    if ( !window.bgmpGdpr || window.bgmpGdpr.isOptedOut() ) {


    fbq( ‘init’, ‘436331036555416’ );
    fbq( ‘track’, ‘PageView’ );

    if ( ‘object’ === typeof mc4wp && mc4wp.forms ) {
    mc4wp.forms.on( ‘subscribed’, function() {
    // Successful MC4WP newsletter signup AJAX form submission.
    fbq( ‘track’, ‘Lead’ );
    } );
    } );

    Virtual Event: The evolving landscape for biosimilars Source link Virtual Event: The evolving landscape for biosimilars

    The post Virtual Event: The evolving landscape for biosimilars – Boston, Massachusetts appeared first on Eminetra.

    Latest Posts

    Don't Miss

    Stay in touch

    To be updated with all the latest news, offers and special announcements.